IRIS UniCatt

Marchetti, Claudia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1.944
NA - Nord America 1.932
AS - Asia 1.500
SA - Sud America 453
AF - Africa 41
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 5.873
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.890
SG - Singapore 700
SE - Svezia 571
IT - Italia 481
BR - Brasile 422
IE - Irlanda 289
CN - Cina 276
ID - Indonesia 171
DE - Germania 160
IN - India 148
FR - Francia 111
RU - Federazione Russa 69
CZ - Repubblica Ceca 61
GB - Regno Unito 44
FI - Finlandia 38
KR - Corea 33
HK - Hong Kong 30
NL - Olanda 30
CA - Canada 20
TR - Turchia 20
VN - Vietnam 20
AT - Austria 18
BE - Belgio 18
UA - Ucraina 16
CI - Costa d'Avorio 15
MX - Messico 14
AR - Argentina 10
IQ - Iraq 10
PK - Pakistan 10
CH - Svizzera 9
IR - Iran 9
JP - Giappone 9
PH - Filippine 9
PL - Polonia 9
BD - Bangladesh 6
CO - Colombia 6
ES - Italia 6
MA - Marocco 6
SA - Arabia Saudita 6
TN - Tunisia 6
AZ - Azerbaigian 5
NP - Nepal 5
UZ - Uzbekistan 5
VE - Venezuela 5
JO - Giordania 4
KE - Kenya 4
EC - Ecuador 3
EG - Egitto 3
KW - Kuwait 3
KZ - Kazakistan 3
LT - Lituania 3
OM - Oman 3
PE - Perù 3
TJ - Tagikistan 3
AE - Emirati Arabi Uniti 2
AU - Australia 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
ET - Etiopia 2
GR - Grecia 2
IL - Israele 2
KG - Kirghizistan 2
PY - Paraguay 2
RO - Romania 2
AL - Albania 1
AM - Armenia 1
AO - Angola 1
BY - Bielorussia 1
CL - Cile 1
CR - Costa Rica 1
CY - Cipro 1
EU - Europa 1
GE - Georgia 1
GT - Guatemala 1
HN - Honduras 1
HU - Ungheria 1
JM - Giamaica 1
KH - Cambogia 1
LB - Libano 1
LK - Sri Lanka 1
LV - Lettonia 1
NO - Norvegia 1
PA - Panama 1
PT - Portogallo 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
ZA - Sudafrica 1
Totale 5.873
Salva come PNG Salva come JPEG
Città #
Ashburn 446
Singapore 375
Dublin 285
Chandler 256
Jakarta 167
Rome 143
Milan 134
Boston 116
Princeton 116
Hyderabad 102
Los Angeles 64
New York 59
Moscow 55
Washington 53
Munich 41
Beijing 38
Brno 38
San Mateo 37
Hefei 33
Frankfurt am Main 32
Seoul 31
São Paulo 29
Hong Kong 27
Helsinki 25
Nuremberg 23
The Dalles 23
Marseille 20
Santa Clara 19
Wilmington 19
Naples 17
Pune 17
Chicago 16
San Francisco 16
Seattle 16
Abidjan 15
Ann Arbor 15
Brussels 15
Rio de Janeiro 15
Bremen 14
Vienna 14
Amsterdam 13
Bari 12
Belo Horizonte 12
Boardman 12
Düsseldorf 12
Brdo 11
Paris 11
Shanghai 11
Olomouc 10
Toronto 10
Ho Chi Minh City 9
London 9
Campinas 8
Fairfield 8
Houston 8
Nanjing 8
Portsmouth 8
Busto Arsizio 7
Cedar Knolls 7
Falkenstein 7
Jacksonville 7
Lauterbourg 7
Redwood City 7
Roubaix 7
Shenyang 7
Bexley 6
Cattolica 6
Hanoi 6
Juiz de Fora 6
New Haven 6
Woodbridge 6
Augusta 5
Baku 5
Betim 5
Brasília 5
Brooklyn 5
Cambridge 5
Curitiba 5
Forest City 5
Maceió 5
Pasig 5
Stockholm 5
Tashkent 5
Zhengzhou 5
Amman 4
Andover 4
Bern 4
Chennai 4
Contagem 4
Dearborn 4
Guangzhou 4
Istanbul 4
Izmir 4
Lappeenranta 4
Leawood 4
Mexico City 4
Milwaukee 4
Montreal 4
Mountain View 4
Pisa 4
Totale 3.369
Salva come PNG Salva come JPEG
Nome #
BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study 148
Management of oligometastatic ovarian cancer recurrence during PARP inhibitor maintenance 96
Chemotherapy resistance in epithelial ovarian cancer: Mechanisms and emerging treatments 95
Molecular profile of brca-negative long survivor high grade serous ovarian cancer patients using a somatic multigene panel 92
Feasibility of tumor testing for BRCA status in high-grade serous ovarian cancer using fresh-frozen tissue based approach 87
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. 81
Ovarian reserve after chemotherapy in breast cancer: A systematic review and meta-analysis 81
Epithelial ovarian cancer and brain metastases: might the BRCA status, PARP inhibitor administration, and surgical treatment impact the survival? 77
Ovarian cancer onset across different BRCA mutation types: a view to a more tailored approach for BRCA mutated patients 75
BRCA status and platinum sensitivity in advanced ovarian cancer according to Chemotherapy Response Score 72
Diet and Chemotherapy: The Effects of Fasting and Ketogenic Diet on Cancer Treatment 67
Tolerability of bevacizumab in elderly ovarian cancer patients (Turbo study): A case-control study of a real-life experience 66
Quality of life in patients with advanced ovarian cancer after primary debulking surgery versus neoadjuvant chemotherapy: Results from the randomised SCORPION trial (NCT01461850) 65
Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer before olaparib maintenance: Still getting any benefit? A case-control study 65
Cytoreductive surgery for advanced epithelial ovarian cancer in the poly(ADP-ribose) polymerase inhibitors era—Is it time for a new paradigm shift? A systematic review and meta-analysis 62
Fertility preservation in patients with BRCA mutations or Lynch syndrome 62
Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial 59
BRCA testing on buccal swab to improve access to healthcare and cancer prevention: A performance evaluation 59
What’s beyond BRCA Mutational Status in High Grade Serous Ovarian Cancer? The Impact of Hormone Receptor Expression in a Large BRCA-Profiled Ovarian Cancer Patient Series: A Retrospective Cohort Study 58
Optimizing the number of cycles of neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma: A propensity-score matching analysis 58
Risk reducing surgery with peritoneal staging in BRCA1-2 mutation carriers. A prospective study 57
High resolution melting profiles (HRMPs) obtained by magnetic induction cycler (MIC) have been used to monitor the BRCA2 status highlighted by next generation tumor sequencing (NGTS): a combined approach in a diagnostic environment 57
Tumor BRCA testing in ovarian cancer and EQA scheme: our experience of a critical evaluation 56
NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer 55
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 54
Neoadjuvant chemoteraphy in unresectable ovarian cancer with olaparib and weekly carboplatin plus paclitaxel: A phase II, open label multicenter study (NUVOLA trial) 54
Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients 54
BRCA Mutation Status to Personalize Management of Recurrent Ovarian Cancer: A Multicenter Study 53
Letrozole in the management of advanced ovarian cancer: An old drug as a new targeted therapy 53
Bevacizumab as maintenance treatment in BRCA mutated patients with advanced ovarian cancer: A large, retrospective, multicenter case-control study 53
Nomogram to predict feasibility of minimally invasive interval debulking surgery in advanced ovarian cancer 53
Pembrolizumab for advanced cervical cancer: safety and efficacy 52
MEK inhibitor as single agent in low grade serous ovarian and peritoneal cancer: a systematic review and meta-analysis 50
A common pattern of somatic mutations in t-MDS/AML of patients treated with PARP inhibitors for metastatic ovarian cancer 50
Olaparib as maintenance therapy in patients with BRCA 1–2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome 50
A common pattern of somatic mutations in t-MDS/AML of patients treated with PARP inhibitors for metastatic ovarian cancer 49
MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1 48
Trabectedin plus pegylated liposomal doxorubicin in patients with disease progression after PARP inhibitor maintenance: a real-life case-control study 47
Medical treatment of patients with gynecologic cancer during the COVID-19 pandemic 47
Needleoscopic-assisted risk-reducing bilateral salpingo-oophorectomy in BRCA1/2 mutation carriers: Peri-operative outcomes and psychological impact 46
Vulvo-vaginal reconstruction after radical excision for treatment of vulvar cancer: Evaluation of feasibility and morbidity of different surgical techniques 46
The impact of secondary cytoreductive surgery in platinum sensitive recurrent ovarian cancer treated with upfront neoadjuvant chemotherapy and interval debulking surgery 46
Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel 46
Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: A retrospective MITO group study 45
Brain metastases in patients with EOC: Clinico-pathological and prognostic factors. A multicentric retrospective analysis from the MITO group (MITO 19) 44
Evolution of Clinical Trials in Ovarian Cancer Management over the Past 20 Years: Never Settle Down, Always Go beyond 44
A retrospective analysis of trabectedin infusion by peripherally inserted central venous catheters: A multicentric Italian experience 42
Ovarian cancer predisposition beyond BRCA1 and BRCA2 genes 41
The INCH trial - Induction chemotherapy in patients with bulky anal canal cancer: Evaluation of the pilot phase 40
The prognostic role of systemic inflammatory markers in apparent early-stage ovarian cancer 39
Beyond the beyond: First case of 9 cytoreductive surgeries in a long-surviving ovarian cancer patient: Case report 39
Detecting Large Germline Rearrangements of BRCA1 by Next Generation Tumor Sequencing 38
A commentary on the discrepancy between blood and tumour BRCA testing: An open question 37
Response to: Should we or should we not? Risk reduction bilateral salpingectomy for BRCA mutation carriers 37
Update on fertility-sparing treatment in primary and recurrent endometrial cancer 36
The Role of Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer: A Systematic Review and Meta-Analysis 35
Ixabepilone for the treatment of endometrial cancer 35
Role of minimally invasive secondary cytoreduction in patients with recurrent ovarian cancer 34
Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors 33
First-line treatment of women with advanced ovarian cancer: Focus on bevacizumab 33
Targeted drug delivery via folate receptors in recurrent ovarian cancer: A review 33
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 32
New windows of surgical opportunity for gynecological cancers in the era of targeted therapies 32
PARP inhibition: A promising therapeutic target in ovarian cancer 32
Bevacizumab in ovarian cancer: State of the art and unanswered questions 32
Secondary cytoreductive surgery: Surgical approach to bulky aortic nodes, splenic metastases and mesenteric disease 32
Care after premenopausal risk-reducing salpingo-oophorectomy in high-risk women: Scoping review and international consensus recommendations 31
Vaginectomy: a minimally invasive treatment for cervical cancer vaginal recurrence 31
Rucaparib Maintenance in Upfront Ovarian Cancer: The Long-Lasting Challenge of Predicting Response to Poly (ADP-ribose) Polymerase Inhibitors 30
Midtrimester isolated short femur and perinatal outcomes: A systematic review and meta-analysis 30
Olfactomedin-4 regulation by estrogen in the human endometrium requires epidermal growth factor signaling 30
Vulvodynia: Current opinion and treatment strategies 30
Immune check-point in endometrial cancer 30
Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression 30
Current knowledge and open issues regarding Bevacizumab in gynaecological neoplasms 29
Hemoglobin variation and blood transfusion rates in patients affected by locally advanced cervical cancer undergoing neo-adjuvant chemotherapy followed by radical surgery: The role of erythropoietic growth factors 29
Chemotherapy in elderly patients with gynecological cancer 29
Reactive lymphoid hyperplasia of liver mimicking late ovarian cancer recurrence: Case report and literature review 29
Olaparib, PARP1 inhibitor in ovarian cancer 29
Dose-dense weekly chemotherapy in advanced ovarian cancer: An updated meta-analysis of randomized controlled trials 29
Bilateral Risk-Reduction Mastectomy in BRCA1 and BRCA2 Mutation Carriers: A Meta-analysis 29
Skin metastases from endometrial cancer treated with electrochemotherapy: Case report and review of literature 29
Threatened abortion and late-pregnancy complications: A case-control study and review of literature 29
Cervical cancer: Are there potential new targets? an update on preclinical and clinical results 29
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 29
Adjuvant chemotherapy does not improve disease-free survival in FIGO stage IC ovarian granulosa cell tumors: The MITO-9 study 28
Survival and toxicity in neoadjuvant chemotherapy plus surgery versus definitive chemoradiotherapy for cervical cancer: A systematic review and meta-analysis 28
Hormone therapy in oophorectomized BRCA1/2 mutation carriers 28
Efficacy and toxicity of bevacizumab in recurrent ovarian disease: An update meta-analysis on phase III trials 28
Dualistic classification of epithelial ovarian cancer: Surgical and survival outcomes in a large retrospective series 28
Integrating clinical-molecular data to predict PARP inhibitors efficacy in advanced ovarian cancer patients after interval cytoreductive surgery 27
Weekly versus three weeks chemotherapy for advanced ovarian cancer: A meta-analysis 27
An overview of early investigational therapies for chemoresistant ovarian cancer 27
From the tailoring of adjuvant treatment to the tailoring of pelvic and aortic lymphadenectomy in stage i endometrial cancer 27
Overcoming platinum resistance in ovarian cancer treatment: from clinical practice to emerging chemical therapies 27
Management of Endometriomas 27
Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A meta-analysis 27
Imaging strategy in recurrent ovarian cancer: a practical review 27
Fighting against the challenge of treating patients with late-line ovarian cancer: are we there yet? 26
Bartholin gland cancer 26
Totale 4.515
Salva come PNG Salva come JPEG
Categoria #
all - tutte 48.749
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 48.749
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203 0 0 0 0 0 0 0 0 0 0 0 3
2020/202175 10 2 0 2 4 0 27 4 2 9 15 0
2021/2022480 17 3 3 23 5 8 14 46 11 27 146 177
2022/20231.358 200 190 113 97 84 192 90 93 148 37 73 41
2023/20241.582 35 337 77 203 87 258 134 43 24 66 172 146
2024/20252.511 61 53 223 74 149 91 74 83 483 328 540 352
Totale 6.086